Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Robert F. Kennedy Jr. is set to appear before the Senate Finance Committee for the first of two confirmation hearings as ...